Renaissance Group LLC Supernus Pharmaceuticals, Inc. Transaction History

Renaissance Group LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 12, 2020	SELL	$19.93 - $29.13 $209,185 - $305,748	-10,496 Closed	0 $0
Q3 2019 Oct 31, 2019	BUY	$25.47 - $33.37 $9,678 - $12,680	380 Added 3.76%	10,496 $288,000
Q2 2019 Aug 13, 2019	BUY	$29.96 - $38.87 $6,051 - $7,851	202 Added 2.04%	10,116 $335,000
Q1 2019 Apr 30, 2019	SELL	$32.77 - $41.99 $23,954 - $30,694	-731 Reduced 6.87%	9,914 $347,000
Q4 2018 Feb 04, 2019	BUY	$30.84 - $49.51 $13,477 - $21,635	437 Added 4.28%	10,645 $354,000
Q3 2018 Nov 13, 2018	BUY	$42.7 - $56.55 $12,938 - $17,134	303 Added 3.06%	10,208 $514,000
Q2 2018 Aug 07, 2018	SELL	$44.1 - $59.85 $34,001 - $46,144	-771 Reduced 7.22%	9,905 $593,000
Q1 2018 Apr 30, 2018	BUY	$37.15 - $46.9 $10,587 - $13,366	285 Added 2.74%	10,676 $489,000
Q4 2017 Feb 06, 2018	BUY	$36.4 - $42.6 $3,494 - $4,089	96 Added 0.93%	10,391 $414,000
Q3 2017 Nov 08, 2017	BUY	$36.75 - $49.65 $378,341 - $511,146	10,295	10,295 $412,000

281

60.6M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.93B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Renaissance Group LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Group LLC with notifications on news.